Dr. Prasanth Manohar, Ph.D., – Page 52 – PHAGElogist

Phage Therapy Shows Promise for Drug-Resistant Infections

The current push to limit antibiotic use in humans and animals has led to a resurgence of interest in therapies using bacteriophages or phage viruses to infect and destroy bacteria.…

Cystic Fibrosis Patients Turn to Experimental Phage Therapy

Microphage therapy has not been approved by the Food and Drug Administration, but there is growing interest in the treatment for cystic fibrosis. Mallory Smith was diagnosed with cystic fibrosis,…

Where are we on the road to phage therapy?

As issues of product consistency, standardization and specificity are being tackled, can phage therapeutics—long oversold and overhyped—finally realize their antibacterial potential? Last May, an international team of researchers and clinicians…

FDA Approves Bacteriophage Trial. Is it time to approach CDSCO/ DCGI in India?

The first US clinical trial of intravenously administered bacteriophage therapy has received FDA approval. Physician researchers at the University of California San Diego (UCSD) School of Medicine will conduct the trial in…

The race to beat antibiotic resistance is on – so where do phages fit in?

The first antibiotic was discovered by Paul Ehrlich in 1909 and cured syphilis-infected rabbits. At that time about 10% of the population of London were infected with syphilis and there…

Phage Therapy Win: Mycobacterium Infection Halted

A 15 year-old patient with cystic fibrosis and a chronic antibiotic-resistant Mycobacterial infection was treated with a three-phage cocktail. When Graham Hatfull, PhD, a professor at the University of Pittsburgh…

In India- “SOCIETY FOR BACTERIOPHAGE RESEARCH AND THERAPY”

Join @ http://www.sbrtganga.com/

Antibiotics Aren’t Profitable Enough for Big Pharma to Make More

7 May 20197 May 2019

Public health experts are calling for new incentives to reward companies for bringing drugs that are effective against resistant strains to market. https://www.bloomberg.com/news/articles/2019-05-03/antibiotics-aren-t-profitable-enough-for-big-pharma-to-make-more Achaogen Inc. spent 15 years racing to develop…

The cost of antimicrobial resistance

India must brace for the economic shocks from uncontrolled antimicrobial resistance Even though antimicrobial resistance is acknowledged by policymakers as a major health crisis, few have considered its economic impact. Now, a…

How about this article? Says more about R&D in India

The content published here has no link with this webpage admin. This article was originally published on the Telegraph. A term greatly beloved of the Narendra Modi government is ‘surgical…